IMRX - Immuneering stock rebounds 34% following last week's selloff
2024-03-18 16:13:07 ET
More on Immuneering
- TD Cowen cuts Immuneering to market perform, cites Phase 1 data
- Immuneering cancer drug shows initial clinical activity in early-stage trial
- Seeking Alpha’s Quant Rating on Immuneering
- Historical earnings data for Immuneering
- Financial information for Immuneering